What is Oxytocin?
Oxytocin is a nine-amino acid neuropeptide produced in the hypothalamus and released from the posterior pituitary. It plays fundamental roles in social bonding, trust, empathy, sexual reproduction, and maternal behavior. It is FDA-approved as Pitocin for labor induction and postpartum hemorrhage. Intranasal oxytocin is being studied for autism, social anxiety, and PTSD.
What Oxytocin Is Investigated For
Oxytocin is used across two largely separate clinical domains: an established obstetric role (IV Pitocin for labor induction, augmentation, and postpartum hemorrhage) and a research-driven off-label psychiatric/social use (intranasal oxytocin for autism, PTSD, social anxiety, postpartum depression, and bonding-related applications). The strongest evidence is overwhelmingly in obstetrics — decades of large-scale clinical use, clinical use since du Vigneaud's 1950s synthesis, and a place on the WHO Model List of Essential Medicines. The intranasal neuropsychiatric evidence is mixed-to-disappointing: the large SOARS-B trial in autism found no benefit on its primary social-withdrawal outcome in children and adolescents, contradicting smaller earlier-trial signals, and no FDA approval exists for any behavioral, psychiatric, or social-cognition indication. Foundational uncertainties — including how much intranasal oxytocin actually reaches the brain, and context-dependent effects on trust vs. out-group bias — remain unresolved. Strong in obstetrics; the 'love hormone' narrative substantially overstates the behavioral evidence.
History & Discovery
Oxytocin was first isolated and chemically characterized by Vincent du Vigneaud and colleagues at Cornell University Medical College, who determined its nine-amino-acid sequence and accomplished the first laboratory synthesis of a polypeptide hormone in 1953. Du Vigneaud received the Nobel Prize in Chemistry in 1955 specifically for this work, which established the template for subsequent peptide-hormone chemistry. The functional biology — uterine contraction, milk ejection — had been recognized since Henry Dale's experiments in the early 1900s with posterior-pituitary extracts, but du Vigneaud's work turned oxytocin into a defined molecule that could be synthesized and administered clinically. Pitocin (synthetic oxytocin for IV use) became the standard agent for labor induction and augmentation and for prevention and treatment of postpartum hemorrhage, roles it still fills as one of the most widely used medicines in obstetrics worldwide. A separate research wave beginning in the 1970s and 1980s reframed oxytocin as a central nervous system neuromodulator — work in voles and other animals established its role in pair bonding, parental behavior, and social recognition. That reframing, amplified by popular-science writing, gave rise to oxytocin's 'love hormone' identity and to the 2000s–2010s wave of intranasal human studies investigating whether exogenous oxytocin could enhance social cognition, trust, and behavioral outcomes in autism, PTSD, social anxiety, and postpartum depression. The clinical-trial results from that wave have been mixed-to-disappointing, as in the large SOARS-B trial for autism — a significant gap between the headline framing and the reality of the data.
How It Works
Oxytocin is the brain's bonding hormone. It's released during hugging, childbirth, and intimate moments. It promotes feelings of trust, connection, and calm by acting on specific brain regions involved in social behavior and stress response.
Oxytocin binds to the oxytocin receptor (OXTR), a Gq-coupled GPCR expressed in the brain (amygdala, hypothalamus, nucleus accumbens), uterus, and mammary glands. Central effects include reduced amygdala reactivity to threatening stimuli, enhanced social salience processing, and modulation of the HPA stress axis. Peripheral effects include uterine smooth muscle contraction and milk ejection. Intranasal administration is thought to reach the brain via olfactory and trigeminal nerve pathways, though the exact CNS penetration is debated.
Evidence Snapshot
Human Clinical Evidence
Extensive for obstetric use. Mixed-to-disappointing for psychiatric/social applications — a May 2026 meta-analysis of 42 RCTs (N=1,922; Neuroscience & Biobehavioral Reviews) found a small, non-significant overall effect of intranasal oxytocin on mental-disorder symptoms (g=0.17, 95% CI [-0.05, 0.38]) with substantial between-trial heterogeneity (I²=77.4%) and a small significant effect only in schizophrenia spectrum disorders (g=0.12); removing two outlier substance-use trials shrank the pooled effect to g=0.05 with no heterogeneity. A separate 2026 meta-analysis of autism RCTs (733 participants) found no effect on social functioning (SMD −0.05).
Animal / Preclinical
Comprehensive. Oxytocin biology is one of the most studied neuropeptide systems.
Mechanistic Rationale
Very strong. OXTR signaling and social neuroscience are well-characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about Oxytocin:
- 01Resolution of the mixed clinical-trial picture in autism — the large SOARS-B trial (Sikich et al., 2021) found no significant benefit of intranasal oxytocin on social behavior in children and adolescents with autism, contradicting earlier smaller-trial signals. The field has not yet reconciled why smaller trials reported positive effects that did not replicate at scale, and whether any responder subgroup can be identified remains open. A May 2026 Neuroscience & Biobehavioral Reviews precision-medicine framework paper from the Guastella group lays out the current case for stratifying autistic populations by biomarker, sex, developmental stage, and OXTR genotype before declaring intranasal oxytocin a failed intervention — a recent synthesis of the autism evidence and a proposed path forward.
- 02CNS penetration after intranasal administration — whether, and how much, intranasal oxytocin actually reaches the brain vs. acting peripherally is a foundational uncertainty that affects interpretation of every behavioral trial.
- 03Dose-response curves for behavioral endpoints — whether standard 24 IU doses are sub-optimal, optimal, or supra-optimal for different behavioral outcomes is not well characterized; some evidence suggests inverted-U dose-response and sex differences.
- 04Long-term effects of chronic intranasal oxytocin on endogenous oxytocin system function — whether chronic exogenous exposure downregulates OXTR expression or disrupts endogenous signaling is not well studied in adults. In one 4-week pediatric autism RCT, oxytocin raised salivary oxytocin and lowered OXTR DNA methylation, which points away from downregulation; the rise was gone by the 4-week follow-up.
- 05Sex, genotype, and context effects — OXTR polymorphisms, participant sex, social context of administration, and baseline attachment style all appear to modulate response, and trials that have not stratified by these factors may have obscured real effects.
- 06Alcohol use disorder — a 100-person, 12-week multisite RCT (2026) found intranasal oxytocin up to 70 IU/day did not reduce heavy drinking days, and a 2026 meta-analysis of six RCTs found no credible effect (Bayesian BF01 = 4.74 favoring the null).
- 07Postpartum depression and maternal bonding trials — most trials in this space are small, and meaningful Phase III evidence is lacking despite promising signals.
- 08Oxytocin substitution in AVP deficiency / central diabetes insipidus — the OxyTUTION trial (BMJ Open 2026, NCT06036004) is examining whether intranasal oxytocin (24 IU twice daily) provides clinical benefit in AVP-deficient patients, on the rationale that hypothalamic damage causing AVP deficiency often co-damages adjacent oxytocin neurons. The 28-day trial (24 IU twice daily) has a primary outcome of improvement in either trait anxiety or emotion recognition; results are pending.
- 09Obesity and food-intake regulation — a 61-person, 8-week RCT of intranasal oxytocin (24 IU four times daily; NEJM Evidence 2024) found no difference in weight change (0.20 vs 0.26 kg), and a June 2026 crossover RCT in 24 people (Diabetes, Obesity and Metabolism) found that a 4.5-hour intravenous infusion of oxytocin producing supraphysiological plasma concentrations (~400 pg/mL) had no effect on ad libitum food intake, appetite sensations, or postprandial glucose in individuals with obesity. With both the intranasal and IV routes now producing mixed-to-null findings, the case for oxytocin as a metabolic therapeutic is materially weaker than it appeared a few years ago.
Forms & Administration
IV infusion (Pitocin, for labor: started at 0.5–1 mU/min and raised by 1–2 mU/min every 30–60 minutes). Intranasal spray (research: 24-40 IU per dose). IM injection for postpartum hemorrhage. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
For the approved IV obstetric use (Pitocin for labor induction/augmentation), the label starts at 0.5–1 mU/min and raises the rate by 1–2 mU/min every 30–60 minutes until a normal contraction pattern is reached. The label says rates above 9–10 mU/min are rarely required at term, though some hospital protocols titrate higher; a secondary analysis of a 1,003-person trial found no significant rise in adverse outcomes when rates exceeded 20 mU/min. For prevention of postpartum hemorrhage, the label dose is 10 units IM after delivery of the placenta, or 10–40 units added to up to 1,000 mL of IV fluid and infused at the rate needed to control uterine atony. For off-label intranasal research use, most trials have used 24–40 IU per dose; doses vary widely: one pediatric autism trial used 12 IU twice daily, SOARS-B targeted 48 IU per day, an obesity trial used 24 IU four times daily, and a 2026 alcohol-use-disorder trial went up to 70 IU per day. Buccal and sublingual formulations exist but are less standardized.
Frequency
IV oxytocin for labor is a continuous titrated infusion in a monitored setting, not a patient-administered regimen. Intranasal oxytocin in research protocols has typically been administered 20–40 minutes before a target task or stimulus (single-dose studies) or once to twice daily for weeks in chronic-administration studies. Postpartum hemorrhage dosing is situational rather than scheduled.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
IV oxytocin is episodic to the obstetric event. Intranasal oxytocin research protocols have ranged from single acute doses to 4–12 week chronic daily administration (e.g., autism trials, postpartum depression studies). No consensus duration exists for off-label use; most trials cover 4–12 weeks of daily dosing; the largest autism trial, SOARS-B, ran 24 weeks.
Protocol Notes
Bioavailability differs enormously by route. IV oxytocin reaches target tissues directly and effects on uterine smooth muscle are immediate and titratable. Intranasal oxytocin aims to reach the CNS via olfactory and trigeminal pathways, but the actual fraction reaching brain tissue is debated — some imaging and CSF studies suggest meaningful central penetration, while others argue that much of the effect may be mediated peripherally or via vagal afferents rather than direct brain uptake. Buccal and sublingual routes bypass first-pass metabolism but with even less well-characterized CNS delivery. Oral oxytocin is not effective — the peptide is rapidly degraded in the GI tract. Compounding pharmacies sell intranasal oxytocin sprays for off-label use; quality and actual concentration vary between sources. Research use of intranasal oxytocin almost always specifies the delivery device, concentration, and timing because these variables meaningfully affect pharmacologic exposure. IV Pitocin must be administered in a monitored obstetric setting because of the real risk of uterine hyperstimulation, fetal distress, and water intoxication at higher or prolonged doses. A 2026 Cochrane review (9 trials, 4,814 women) found that stopping IV oxytocin once active labor begins may make little or no difference to cesarean rates (RR 0.98) and may reduce uterine hyperstimulation (RR 0.65, low certainty), at the cost of a longer active phase. Two 2025–2026 analyses linked higher prophylactic postpartum oxytocin doses or infusion rates with less bleeding.
IV and IM oxytocin are prescription medicines restricted to clinical use. Intranasal oxytocin for psychiatric, behavioral, or social applications is off-label in the United States — no FDA approval exists for autism, PTSD, social anxiety, postpartum depression, or bonding-related uses. Any off-label use belongs under physician supervision.
Timeline of Effects
Onset
IV oxytocin effects on uterine contraction begin within minutes, which is why labor induction is titrated in real time with continuous fetal and contraction monitoring. Intranasal oxytocin in acute research paradigms is typically administered 20–40 minutes before the target task, corresponding to the window in which both peripheral plasma levels and presumed central effects are measurable. Subjective or interpersonal effects in single-dose intranasal studies, when observed, appear in that same 30–60 minute window.
Peak Effect
IV effects on uterine contraction peak quickly and are sustained by the continuous infusion; half-life in plasma is short (roughly 1–6 minutes). Intranasal plasma peak is typically observed within 15–30 minutes post-administration; central effects measured by functional MRI or behavioral endpoints typically peak in the 30–60 minute window and begin to fade over 2–4 hours. Chronic administration studies measure cumulative endpoints at weeks, with most peak effects reported at 4–8 weeks.
After Discontinuation
IV oxytocin clears quickly — plasma half-life is measured in minutes — and effects on uterine tone recede after the infusion is stopped: the label says the uterine response to IV oxytocin subsides within 1 hour, while after an IM injection it starts in 3–5 minutes and lasts 2–3 hours. Intranasal oxytocin clears similarly quickly from plasma, and acute behavioral effects dissipate over hours. For chronic intranasal use, the available trial evidence does not document a meaningful withdrawal or rebound pattern, though long-term post-cessation follow-up data is limited. The behavioral effects claimed in some chronic-administration studies were largely inconsistent at post-treatment follow-up, consistent with the mixed-to-null efficacy picture overall.
Common Questions
Can intranasal oxytocin improve relationships?
Some studies show intranasal oxytocin can increase trust, empathy, and social cognition in controlled settings. However, effects are context-dependent and not universally positive — it can also increase envy and out-group bias. It's not a simple 'love drug.'
What's the difference between IV Pitocin and intranasal oxytocin?
They are the same molecule but in entirely different clinical contexts. IV Pitocin is FDA-approved, administered as a titrated infusion in a monitored obstetric setting for labor induction/augmentation and postpartum hemorrhage; effects on uterine smooth muscle are immediate and the indication is firmly evidence-based. Intranasal oxytocin is off-label, used in research and compounded products to target central nervous system effects on social cognition, anxiety, autism symptoms, and bonding. Bioavailability and target tissues differ enormously: IV reaches uterine tissue directly, while intranasal aims for the brain via olfactory and trigeminal pathways with debated CNS penetration. The strong evidence base for IV obstetric use does not transfer to the intranasal psychiatric use.
Does intranasal oxytocin help with autism symptoms?
The most rigorous answer is no, at least not for the social-withdrawal outcomes that have been the primary target. The large SOARS-B trial (Sikich et al., 2021) — the best-powered RCT of intranasal oxytocin in autism — found no significant benefit on its primary social-withdrawal outcome in children and adolescents. Smaller earlier trials reported mixed positive signals that did not replicate at scale. A May 2026 meta-analysis of 42 RCTs across psychiatric indications found only a small, non-significant overall effect (g=0.17). There is ongoing precision-medicine work asking whether biomarker-defined subgroups (sex, OXTR genotype, developmental stage) might respond, but as a general intervention for autism the evidence does not support efficacy. Oxytocin is not FDA-approved for autism.
Can oxytocin nasal spray improve sexual function or libido?
Evidence is thin and inconsistent. Endogenous oxytocin is released during sexual activity and contributes to pair-bonding and orgasm-related neurobiology, which has driven interest in exogenous oxytocin as a sexual-function aid. Small studies have explored intranasal oxytocin for arousal and partner-directed sexual response with mixed results, and no formulation has earned regulatory approval for any sexual-function indication. For hypoactive sexual desire disorder in premenopausal women, the FDA-approved peptide is bremelanotide (PT-141), which acts on melanocortin receptors via a different mechanism. The 'love hormone' framing has driven off-label experimentation but the controlled evidence does not support reliable aphrodisiac effects.
Is oxytocin nasal spray safe to use long-term?
Long-term safety in healthy individuals using compounded intranasal oxytocin for off-label purposes is not well characterized. Chronic-administration trials have run up to 24 weeks (SOARS-B, 290 children and adolescents with autism) with adverse events similar to placebo, but post-cessation follow-up and multi-year data are limited. Theoretical concerns include downregulation of endogenous OXTR signaling with chronic exogenous exposure, dose-dependent water-retention effects at higher systemic exposure, and unknown interactions with other neuroactive medications. Compounded intranasal products vary in actual concentration and quality between sources. Off-label intranasal use belongs under physician supervision, particularly for anyone taking psychotropics or with cardiovascular, renal, or electrolyte conditions.
How does oxytocin compare with carbetocin?
Carbetocin is a longer-acting oxytocin analog. In the 29,645-woman CHAMPION trial, 100 µg IM of heat-stable carbetocin was noninferior to 10 IU IM oxytocin for preventing blood loss of 500 mL or more after vaginal birth (14.5% vs 14.4%); noninferiority could not be shown for blood loss of 1,000 mL or more because such events were too rare. Heat-stable carbetocin matters where cold storage for oxytocin is unreliable. Carbetocin is not FDA-approved in the US, so American practice still uses oxytocin. Separately, an intranasal carbetocin spray failed its confirmatory Phase 3 trial for hyperphagia in Prader-Willi syndrome in September 2025 and the programme was discontinued.
Does oxytocin help with anxiety or PTSD?
Signals are mixed and not yet clinically actionable. Some acute-dose studies show intranasal oxytocin reduces amygdala reactivity to threatening social stimuli and dampens cortisol responses in stressful paradigms, which is the mechanistic basis for interest in anxiety and PTSD. Trials in social anxiety and PTSD have produced inconsistent results, with effects often modulated by sex, attachment style, baseline symptom severity, and OXTR genotype. The May 2026 meta-analysis across mental disorders found only a small non-significant overall effect. No regulatory body has approved oxytocin for anxiety or PTSD, and standard-of-care treatments (SSRIs, exposure-based therapy, trauma-focused CBT) remain first-line.
Who Oxytocin Is NOT For
- •Significant cephalopelvic disproportion, unfavorable fetal position, or other obstetric contraindications to vaginal delivery — IV oxytocin for labor induction is contraindicated in these settings.
- •Conditions that predispose to uterine rupture, such as previous major surgery on the cervix or uterus including cesarean section, an overdistended uterus, or grand multiparity — the label says oxytocin should not be given in these settings except in unusual circumstances.
- •Hypertonic or hyperactive uterine patterns, fetal distress where delivery is not imminent, or adequate contractions that are not producing progress — escalating oxytocin is contraindicated. It is also contraindicated wherever vaginal delivery is, such as invasive cervical cancer, active genital herpes, total placenta previa, vasa previa, or cord presentation or prolapse.
- •Known hypersensitivity to oxytocin or to components of the formulation (Pitocin contains 0.5% chlorobutanol as a preservative).
- •Prolonged high-dose IV oxytocin without fluid balance monitoring — oxytocin has antidiuretic activity at high doses (the label cites 40–50 mU/min infused for long periods) and can cause water intoxication, hyponatremia, seizures, and coma. Fluid and electrolyte monitoring is essential.
- •Intranasal off-label use in pregnancy — intranasal oxytocin is not used during pregnancy and the obstetric IV route is the only authorized pregnancy use.
Drug & Supplement Interactions
IV oxytocin has several clinically significant obstetric drug interactions. The label reports severe hypertension when oxytocin was given three to four hours after a prophylactic vasoconstrictor used with caudal-block anesthesia. Prostaglandin cervical ripening agents (misoprostol, dinoprostone) are sometimes used sequentially with oxytocin but should be appropriately spaced to avoid hyperstimulation. Cyclopropane anesthesia (rarely used now) has been associated with unexpected hypotension and arrhythmia when combined with oxytocin. At high IV doses, oxytocin has significant antidiuretic effects and should be used cautiously with large volumes of hypotonic fluids or with other drugs that cause water retention, to avoid hyponatremia and water intoxication. Obstetric protocols manage this by restricting total fluid volumes and monitoring electrolytes during prolonged infusions. For intranasal off-label use at typical research doses (24–40 IU), systemic exposure is much lower and major pharmacologic interactions are less prominent, but theoretical interactions with other neuroactive agents exist. Patients on SSRIs, antipsychotics, or other psychotropics should disclose off-label oxytocin use to their prescribing clinician, as clinical data on combinations is limited. The label says oxytocin is cleared largely by the kidney and liver and describes no CYP-mediated interactions.
Safety Profile
Common Side Effects
Cautions
- • IV oxytocin for labor must be carefully monitored
- • Risk of water intoxication with high doses
- • Effects on social behavior are context-dependent
- • Not indicated for elective (non-medically indicated) induction of labor, per the label's boxed notice
What We Don't Know
Long-term effects of chronic intranasal oxytocin on social behavior and brain function are not fully characterized.
Legal Status
United States
Oxytocin injection (Pitocin and generic versions) is FDA-approved for medically indicated induction of labor, stimulation of labor, adjunctive management of incomplete or inevitable abortion, and control of postpartum bleeding. The label carries a boxed notice that Pitocin is not indicated for elective induction of labor (induction with no medical reason), because the data are inadequate to weigh benefits against risks. Prescription-only. Not a controlled substance. Intranasal oxytocin for psychiatric or social behavioral applications is off-label — not FDA-approved for autism, PTSD, social anxiety, postpartum depression, or any other neuropsychiatric indication. Oxytocin is not on FDA's 503A bulk drug substance nomination lists (Categories 1–3, May 2026 update); because it is the active ingredient of an FDA-approved drug, compounding pharmacies can make intranasal formulations under Section 503A for individual patients, but these are off-label uses of a compounded product, not FDA-approved drugs. Research-chemical sale of oxytocin is not authorized.
International
Approved as an obstetric medicine across the EU, UK, Canada, Australia, Japan, and essentially all major markets — oxytocin is on the WHO Model List of Essential Medicines. Intranasal formulations are similarly off-label for psychiatric indications in most Western jurisdictions, with some variation in compounding practice. Regulatory authorities generally have not approved oxytocin for behavioral or social-cognition indications despite the volume of published research.
Sports & Competition
Oxytocin is not named on the WADA 2027 Prohibited List (effective 1 January 2027), and as an approved medicine it falls outside the S0 catch-all for non-approved substances. Obstetric or medical use is not a doping concern. Off-label intranasal use is likewise not restricted under WADA code.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Oxytocin is the 'love hormone' and intranasal spray reliably makes people feel more connected and trusting.
Reality
Acute intranasal oxytocin studies have shown context-dependent effects on social cognition, but the overall picture from the last two decades is mixed and many individual findings have not replicated. Oxytocin can increase in-group trust while increasing out-group bias and envy in certain paradigms. It is not a reliable or simple pro-social drug.
Myth
Intranasal oxytocin is an effective treatment for autism spectrum disorder.
Reality
The SOARS-B trial — the largest and best-powered randomized controlled trial of intranasal oxytocin in ASD — found no significant benefit on its primary social-withdrawal outcome in children and adolescents. Smaller earlier trials reported mixed positive signals that have not replicated at scale. Oxytocin is not an FDA-approved or clinically established treatment for ASD, and the research picture does not support that framing.
Myth
Oxytocin nasal spray is a safe, non-pharmaceutical wellness supplement.
Reality
Oxytocin is a prescription peptide hormone. Intranasal use for behavioral applications is off-label rather than supplement territory. Compounded intranasal oxytocin is a medication, not a wellness product, and should be used under clinician oversight — particularly given the documented risks of water intoxication with high systemic exposure.
Myth
Oxytocin given during labor is the same thing as 'natural' endogenous oxytocin and has no meaningful risks.
Reality
Pitocin (synthetic IV oxytocin) has a well-established and generally favorable safety profile when administered in a monitored obstetric setting, but it is not risk-free. Uterine hyperstimulation, fetal distress, water intoxication at prolonged high doses, and interactions with vasoconstrictors are all documented concerns that are why IV oxytocin for labor is titrated with fetal monitoring.
Myth
Oxytocin is an aphrodisiac or sexual-performance enhancer.
Reality
Oxytocin is released during sexual activity and contributes to pair-bonding neurobiology, but exogenous oxytocin — intranasal or otherwise — is not an approved or clinically effective sexual-performance drug. Evidence that intranasal oxytocin reliably enhances libido, arousal, or sexual function in humans is thin and inconsistent. PT-141 (bremelanotide) is a different peptide with different mechanism and actual FDA approval in that space.
Published Research
42 studiesThe Effect of Intranasal Oxytocin on Social Interaction in Adults and Children With Autism Spectrum Disorders: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
2026 pooled analysis of 12 autism RCTs (733 participants) finding no effect of intranasal oxytocin on social functioning (SMD −0.05, 95% CI −0.20 to 0.10, p=0.54), with almost no between-trial heterogeneity (I²=4%) and no signal in any prespecified subgroup — the quantitative confirmation that SOARS-B was not an outlier but the expected result.
Continuation versus discontinuation of intravenous oxytocin in the active phase of labour.
2026 Cochrane review (9 trials, 4,814 women): stopping IV oxytocin in active labour may make little or no difference to caesarean rates (RR 0.98) and may reduce uterine hyperstimulation (RR 0.65, low certainty).
Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study.
Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Multisite Trial Assessing Efficacy and Safety.
A 12-week double-blind multisite trial in 100 adults with alcohol use disorder: intranasal oxytocin up to 70 IU/day did not reduce the primary endpoint of percentage heavy drinking days, nor craving, mood, sleep or alcohol-related consequences, though it was well tolerated and lowered anger and physical-aggression scores. Its null result is reinforced by the 2026 Bayesian meta-analysis of six RCTs, which found moderate support for no effect at all.
A Quality-Improvement Study Evaluating Three Postpartum Prophylactic Oxytocin Rates and Blood Loss After Vaginal Birth.
Intranasal oxytocin for alcohol use disorder: A systematic review and multilevel, bayesian, and variance meta-analyses of randomized clinical trial data.
Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence
Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials
May 2026 Neuroscience & Biobehavioral Reviews meta-analysis of 42 RCTs (N=1,922) finding a small, non-significant overall effect of intranasal oxytocin on mental-disorder symptoms (g=0.17, 95% CI [-0.05, 0.38], I²=77.4%), with a small significant effect only in schizophrenia spectrum disorders (g=0.12) — the most rigorous quantification to date of the mixed-to-disappointing intranasal evidence base.
Oxytocin substitution therapy in patients with AVP deficiency (central diabetes insipidus): study protocol of a double-blind, randomised placebo-controlled trial
Effects of intranasal oxytocin on fear, pain and aversive memory
Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity
Effects of Prophylactic Oxytocin or Carbetocin on Troponin Release and Postpartum Haemorrhage at Planned Caesarean Delivery: A Double-Blind Randomised Controlled Trial
Boosting oxytocin in postpartum depression: Intranasal oxytocin enhances maternal positive affect and regard for the infant
Results of a Randomized Controlled Trial Examining the Efficacy of Intranasal Oxytocin to Enhance Alcohol Behavioral Couple Therapy
A comparative analysis of the efficacy of intrauterine misoprostol in conjunction with oxytocin versus oxytocin monotherapy for the prophylaxis of primary postpartum haemorrhage
Association of postpartum oxytocin dose and postpartum bleeding outcomes in nulliparous patients at term
Secondary analysis of a 2,404-woman pushing-timing RCT: high-dose postpartum oxytocin was associated with lower postpartum-hemorrhage rates than lower doses (observational comparison).
Impact of chronic intranasal oxytocin administration on face expression processing in autistic children: a randomized controlled trial using fMRI
Oxytocin vs oral misoprostol for PROM induction in nulliparas with unfavorable cervix: a randomized trial
Intranasal Oxytocin for Obesity
NEJM Evidence 2024 RCT in adults with obesity: intranasal oxytocin 24 IU four times daily for 8 weeks did not reduce body weight versus placebo (0.20 vs 0.26 kg).
Oxytocin and social learning in socially anxious men and women
The effect of intranasal oxytocin on neurocognition in people with schizophrenia: A randomized controlled trial
Chronic oxytocin administration stimulates the oxytocinergic system in children with autism
Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial
STOPOXY (Lancet 2023): 21 French maternity units, 2,170 participants analysed; stopping the oxytocin infusion once the active phase was reached did not reduce composite neonatal morbidity versus continuing it (9.6% vs 9.2%, RR 1.0, 95% CI 0.8–1.4) — a trial-level answer to a labour-management question hospital protocols had been split on.
At the Head and Heart of Oxytocin's Stress-Regulatory Neural and Cardiac Effects: A Chronic Administration RCT in Children with Autism
Continuous vs intermittent induction of labor with oxytocin in nulliparous patients: a randomized controlled trial
Hypotension duration and vasopressor requirements following intrathecal oxytocin for Total hip arthroplasty: Secondary analysis of a randomized controlled trial
Preliminary results from a randomized, controlled, cross-over trial of intrathecal oxytocin for neuropathic pain
Maximum Dose Rate of Intrapartum Oxytocin Infusion and Associated Obstetric and Perinatal Outcomes
Secondary analysis of a 1,003-person labor-induction RCT: exceeding 20 mU/min of oxytocin was not associated with significant differences in maternal or perinatal adverse outcomes.
Randomized controlled trial of intrathecal oxytocin on speed of recovery after hip arthroplasty
The effect of intranasal oxytocin on processing emotional stimuli during alcohol withdrawal: A randomized placebo-controlled double-blind clinical trial
A randomized controlled trial examining the effects of intranasal oxytocin on alcohol craving and intimate partner aggression among couples
High- vs low-dose oxytocin in lean and obese women: a double-blinded randomized controlled trial
Vaginal misoprostol and intravenous oxytocin for success of termination in the second-trimester intrauterine fetal demise: A randomized controlled clinical trial
Intranasal oxytocin modulates the salience network in aging
Intranasal oxytocin administration impacts the acquisition and consolidation of trauma-associated memories: a double-blind randomized placebo-controlled experimental study in healthy women
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.
SOARS-B (NEJM 2021): 24-week placebo-controlled trial in 290 children and adolescents with autism; intranasal oxytocin (target 48 IU/day) did not improve social or other function versus placebo, with similar adverse events.
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth.
WHO CHAMPION trial in 29,645 women: heat-stable carbetocin 100 µg IM was noninferior to oxytocin 10 IU IM for preventing blood loss of at least 500 mL after vaginal birth.
Oxytocin and Social Relationships: From Attachment to Bond Disruption
Social bonding: regulation by neuropeptides
Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans
Heinrichs and Domes' 2008 Progress in Brain Research synthesis of the early human work on oxytocin and vasopressin across social stress, social cognition, approach behaviour and aggression, closing with a model that proposed the oxytocin system as a target for treating autism, borderline personality disorder and other socially impairing conditions. It is the clearest statement of the optimism that drove the 2000s–2010s intranasal wave, and reads very differently next to the null meta-analyses that followed.
Amniotomy plus intravenous oxytocin for induction of labour
Popular Stacks Including Oxytocin
Quick Facts
- Class
- Neuropeptide Hormone
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Nov 2026
- Citations
- 42PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.